Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

APL-102 Capsule in Patients With Advanced Solid Tumors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05055518
Recruitment Status : Recruiting
First Posted : September 24, 2021
Last Update Posted : September 24, 2021
Sponsor:
Collaborator:
Zhejiang CrownMab Biotech Co. Ltd
Information provided by (Responsible Party):
Apollomics Inc.

Brief Summary:
This study will evaluate the safety and tolerability of APL-102 Capsule and characterize the pharmacokinetic (PK) profile in advanced solid tumor patients.

Condition or disease Intervention/treatment Phase
Advanced Solid Tumor Drug: APL-102 Capsules Phase 1

Detailed Description:
This study is an open, multicenter dose-escalation study to evaluate the safety and tolerance of APL-102 and obtain the relevant data of APL-102 in patients with advanced solid tumors. In the dose escalation stage, based on the incidence of dose limited toxicity (DLT) and adverse event (AE), explore and determine the maximum tolerated dose (MTD) and phase II recommended dose (RP2D). After RP2D and administration protocol are determined, an extended study will be conducted on 6-10 subjects to further evaluate the safety and antitumor activity of APL-102.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 30 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Intervention Model Description: Subjects will be assigned to a dose level of APL-102 in the order of study entry. A total of seven therapeutic dose levels (1mg, 2mg, 3mg, 5mg, 7mg, 9mg and 11mg) are planned. To reduce the number of subjects exposed to potentially ineffective doses and protect the rights and interests of subjects, rapid titration was used in the low-dose group (1 mg, 2 mg, 3 mg); When approaching the expected effective dose of 5 mg, the "3 + 3" study design was used.
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase I Study on Safety, Tolerance, and Pharmacokinetics of APL-102 Capsule in Patients With Advanced Solid Tumors
Actual Study Start Date : August 2, 2021
Estimated Primary Completion Date : October 31, 2023
Estimated Study Completion Date : December 31, 2023

Arm Intervention/treatment
Experimental: A Phase I, open-labeled multicenter study
APL-102 Capsules
Drug: APL-102 Capsules

Dose escalation: A total of seven dose levels (1mg, 2mg, 3mg, 5mg, 7mg, 9mg and 11mg) are planned.

Dose extension: After RP2D determined, the RP2D dose level will be extended to enroll 6-10 subjects to further evaluated the safety and antitumor activity of APL-102.

Other Name: No other name so far




Primary Outcome Measures :
  1. DLT [ Time Frame: 36 days ]
    Dose limiting toxicities

  2. Adverse Events (AEs) [ Time Frame: From time of informed consent signature to 30 days after the subject's last visit (approximately 1 year) ]
    Adverse events occurred in all subjects during the study treatment according to the National Cancer Institute Common Terminology Standard for adverse events (NCI CTCAE) standard version 5.0


Secondary Outcome Measures :
  1. Incidence of Adverse Events [ Time Frame: From time of informed consent signature to 30 days after the subject's last visit (approximately 1 year) ]
    The incidence of all adverse events with different severity (NCI CTCAE 5.0)

  2. Objective response rate(ORR) [ Time Frame: Approximately 1 year ]
    The objective response rate in patients of advanced solid tumors

  3. Duration of response(DOR) [ Time Frame: Approximately 1 year ]
    The duration of response in patients of advanced solid tumors

  4. Progression-free survival(PFS) [ Time Frame: Approximately 1 year ]
    The progression-free survival in patients of advanced solid tumors

  5. Overall survival(OS) [ Time Frame: Approximately 1 year ]
    The overall survival in patients of advanced solid tumors

  6. Peak plasma concentration (Cmax) [ Time Frame: 36 days ]
    To assess the pharmacokinetic profile in patients with advanced solid tumors.

  7. Time to reach Cmax (Tmax) [ Time Frame: 36 days ]
    To assess the pharmacokinetic profile in patients with advanced solid tumors.

  8. The area under the plasma concentration-time curve from time zero to the last measurable time point (AUC0-t) [ Time Frame: 36 days ]
    To assess the pharmacokinetic profile in patients with advanced solid tumors.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Major Inclusion Criteria:

  1. Male or female, age ≥ 18 and ≤ 75 years old.
  2. Patients with unresectable or metastatic advanced solid tumors confirmed by histology or cytology, and after the failure of standard treatment, or cannot tolerate standard treatment, or have no standard treatment.
  3. There were measurable lesions according to the efficacy evaluation criteria of solid tumors (RECIST version 1.1).
  4. Eastern Cooperative Oncology Group(ECOG) performance status score is 0 to 1.
  5. Life expectancy is more than 3 months after the first administration.
  6. The organ function level must meet the following requirements:

    Aspartate aminotransferase (AST) and Alanine aminotransferase (ALT) ≤ 2.0× upper limit of normal value (ULN) (patients with liver metastasis≤ 5 × ULN). Serum bilirubin ≤ 1.5×ULN (total bilirubin ≤ 3×ULN in patients with Gilbert syndrome). Absolute neutrophil count ≥ 1.5×10^9/L. Platelet count ≥ 100×10^9/ L. Hemoglobin ≥ 9 g / dL.

  7. No other chemotherapy was received within four weeks before the first administration of the trial; All previous anti-tumor treatments, including targeted therapy and endocrine therapy, shall pass through at least five half-lives (or no more than 28 days) after receiving targeted therapy/endocrine therapy, and patient shall recover to the standard level specified in the test from the toxic reaction of the treatment.
  8. For patients who have received radiotherapy for spine and/or peripheral limbs, they can only be enrolled after four weeks and two weeks before the first administration and should recover from the toxic reaction of treatment to the standard level specified in the study.
  9. No major surgery was performed within four weeks before the first administration of APL-102., etc.

Major Exclusion Criteria:

  1. Previous treatment with VEGF(vascular endothelial growth factor)/ VEGFR(vascular endothelial growth factor receptor) inhibitors (except bevacizumab for colorectal cancer).
  2. In addition to the malignancies in the study, patients with systemic diseases leading to poor medical risk (such as uncontrollable infection in the active phase).
  3. Life-threatening diseases, severe organ dysfunction, interference with the absorption or metabolism of APL-102, or other reasons that the researchers believe may endanger the safety of subjects or affect the integrity of research results.
  4. Patients with a history of heart disease or potential risk of heart disease.
  5. Patients with low circulatory function as defined by the New York Heart Association's (NYHA) functional criteria.
  6. Patients with a definite diagnosis of chronic obstructive pulmonary disease, bronchial asthma or interstitial lung disease, or patients with forced expiratory volume in one second/ forced vital capacity (FEV1/FVC) ratio < 80% in pulmonary function test.
  7. Patients with decompensated cirrhosis or history of allogeneic bone marrow transplantation or organ transplantation.
  8. Patients in repeated resting states during screening had mean systolic blood pressure ≥140 mmHg, diastolic blood pressure ≥90 mmHg, or positive proteinuria (allowing antihypertensive agents to control blood pressure).
  9. Patients requiring antiplatelet/anticoagulant therapy (including but not limited to aspirin or low molecular weight heparin sodium and warfarin).
  10. Have a history of human immunodeficiency virus (HIV) infection or HIV antibody positive; or seropositive results consistent with active infection for hepatitis B virus (in case of only hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HBcAb) positive, the examination of Hepatitis B (HBV) DNA copy number is needed) or hepatitis C virus.
  11. Patients with the symptomatic primary brain tumor and/or secondary brain metastasis, uncontrollable antiepileptic drugs and requiring high-dose steroid treatment. Or cerebrovascular accident, transient ischemic attack, or intermittent claudication within six months before treatment.
  12. Patients who need to be treated with drugs metabolized through Cytochrome P450 (CYP450) system, especially those who need to be treated with drugs metabolized through Cytochrome p450 3A4( CYP3A4).
  13. Pregnant or lactating patients., etc.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05055518


Contacts
Layout table for location contacts
Contact: Zhejiang CrownMab Ltd. 0571-83521933 ClinicalTrialsChina@apollomicsinc.com
Contact: Qian Li 0571-83521933 Qian.Li@apollomicsinc.com

Locations
Layout table for location information
China
Cancer Institute and Hospital, Chinese Academy of Medical Sciences Recruiting
Beijing, China
Contact: Yihebali Chi, PhD    010-87788800    yihebalichi@hotmail.com   
Sponsors and Collaborators
Apollomics Inc.
Zhejiang CrownMab Biotech Co. Ltd
Investigators
Layout table for investigator information
Principal Investigator: Yihebali Chi, PhD Investigator
Layout table for additonal information
Responsible Party: Apollomics Inc.
ClinicalTrials.gov Identifier: NCT05055518    
Other Study ID Numbers: APL-102-01
First Posted: September 24, 2021    Key Record Dates
Last Update Posted: September 24, 2021
Last Verified: September 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasms